Population pharmacokinetics is the study of the sources and correlates of variability in drug concentrations among individuals who are the target patient population receiving clinically relevant doses. Unlike traditional pharmacokinetic studies that intensively sample a small number of healthy volunteers, population pharmacokinetics analyzes sparse concentration data collected from a large number of patients under routine clinical conditions. This approach quantifies both typical pharmacokinetic behavior and the interindividual and intraindividual variability around the typical values.

NONMEM 方法论

The standard analytical tool for population pharmacokinetic analysis is NONMEM (Nonlinear Mixed Effects Modeling) , developed at the University of California, San Francisco. NONMEM 实现了一种非线性混合效应建模方法，可同时估计固定效应和随机效应。 Fixed effects are the typical population parameters: clearance, volume of distribution, absorption rate constant, and the influence of covariates such as weight, age, or renal function on these parameters. 随机效应量化在考虑固定效应后仍然无法解释的变异性。

The random effects are divided into interindividual variability (IIV) , representing differences between subjects in pharmacokinetic parameters, and residual variability, representing the difference between the model-predicted and observed concentrations within an individual.残余变异性包括测量误差、模型错误指定和个体内随时间变化的变异性。 By partitioning variability into these components, population pharmacokinetic analysis provides a comprehensive description of drug disposition across the target population.

固定和随机效应

群体药代动力学的结构模型使用房室方程定义了典型的药代动力学特征。例如，具有一阶消除的单室模型描述了典型的间隙和分布体积。然后，随机效应模型描述了各个参数如何偏离典型值。 Interindividual variability is typically modeled using an exponential error model: the individual parameter equals the typical parameter multiplied by e to the power of eta, where eta is assumed to be normally distributed with a mean of zero and a variance omega squared.

协变量被纳入固定效应模型中以解释个体间的变异性。 Common covariates include weight, age, sex, serum creatinine or creatinine clearance for renally eliminated drugs, and measures of hepatic function for hepatically cleared drugs.协变量模型可以使用线性或非线性关系，例如间隙按重量提高到0.75次方的异速缩放。添加协变量应该足以改善模型拟合，以证明增加的复杂性是合理的。

研究设计注意事项

群体药代动力学研究通常使用稀疏采样，其中每个患者仅提供少量浓度测量值。这种设计对于常规临床护理来说是实用的，并且允许纳入传统设计中难以研究的患者群体，例如危重患者、新生儿或患有多种合并症的老年患者。 The optimal sampling design for population studies seeks to collect samples at informative times across the dosing interval from different patients, a concept known as optimal design.

The number of subjects in a population pharmacokinetic study is typically larger than in traditional studies, with 50 to several hundred subjects being common.实际数量取决于模型的复杂性、预期变异性以及要评估的协变量的数量。在设计阶段使用基于仿真的方法来确定以足够的精度估计参数所需的样本大小。

个体间和个体内变异性

Understanding the magnitude of interindividual variability is critical for determining whether a fixed dosing regimen is adequate or whether individualized dosing is necessary.对于个体差异较低的药物，标准剂量在大多数患者中产生相似的浓度。 For a drug with high interindividual variability, patients receiving the same dose may have widely different concentrations, and dose individualization based on patient characteristics or therapeutic drug monitoring is warranted.

个体内变异性描述了个体药代动力学随时间的变化，这可能是由于疾病进展、药物相互作用或生理状态的变化造成的。 Quantifying intraindividual variability helps determine the frequency of monitoring needed and the reliability of a single concentration measurement for predicting future concentrations.

在特殊人群中的应用

群体药代动力学分析对于研究传统临床试验中代表性不足的特殊人群的药物处置特别有价值。 Pediatric population pharmacokinetic studies have characterized the maturation of drug-metabolizing enzymes and renal function, enabling evidence-based dose recommendations for children of different ages.老年研究量化了与年龄相关的生理变化对药物清除的影响。对肾或肝功能不全患者的研究为剂量调整建议提供了药代动力学基础。

该方法还用于评估遗传多态性对药物处置的影响。通过将基因型作为群体模型中的协变量，可以量化 CYP2D6、CYP2C9、CYP2C19 和其他多态性酶对药物清除的影响，支持基因型指导的给药策略。

贝叶斯估计实践

群体药代动力学模型是治疗药物监测中贝叶斯估计的基础。 The population model provides prior information about the typical parameter values and their variability, which is updated with the patient’s own concentration measurements to obtain individualized parameter estimates. This Bayesian approach allows precise dose individualization even with sparse sampling, making it feasible to optimize therapy in routine clinical practice.

群体药代动力学原理与贝叶斯反馈的整合改变了万古霉素和氨基糖苷类药物的管理，使临床医生能够比传统给药方法更快地达到目标浓度并更一致地维持目标浓度。随着计算工具变得越来越容易获得，群体药代动力学指导的剂量正在扩展到更广泛的药物范围。